

Clinical Oversight Review Board (CORB) Criteria for Prescribing Teclistamab-cqyv (Tecvayli)

Non-Formulary **teclistamab-cqyv (Tecvayli)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Patient is at least 18 years of age
- Patient has a diagnosis of relapsed or refractory multiple myeloma
- ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1
- Patient has received at least 4 prior therapies including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody

kp.org

Revised: 03/09/23
Effective: 05/04/23

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest